SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fleisch H 1991 Bisphosphonates: Pharmacology and use in the treatment of tumor-induced hypercalcemia and metastatic bone disease. Drugs 42: 919944.
  • 2
    Delmas P, Meunier PJ 1997 The management of Paget's disease of bone. N Engl J Med 336: 558566.
  • 3
    Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora II AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333: 14371443.
  • 4
    Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH 1992 Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33: 16571663.
  • 5
    Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ 1998 Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including rats. J Bone Miner Res 13: 581589.
  • 6
    Frith JC, Mönkkönen J, Blackburn GM, Russell RGG, Rogers MJ 1997 Clodronate and liposome-encapsulated clodronate are metabolized to atoxic ATP analog, adenosine 5′-β,γ-dichloromethylene triphosphate, by mammalian cells in vitro. J Bone Miner Res 12: 13581367.
  • 7
    Delmas PD, Chapuy MC, Edouard C, Meunier PJ 1987 Beneficial effects of aminohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate. Am J Med 83: 276282.
  • 8
    O'Rourke NP, McCloskey EV, Rossini S, Coleman RE, Kanis JA 1994 Treatment of malignant hypercalcaemia with aminohexane bisphophonate (neridronate). Br J Cancer 69: 914917.
  • 9
    Friedewald WT, Levy RI, Frerickson DS 1972 Estimation of the concentration of low-density lipoprotein-cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 18: 499505.
  • 10
    Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA 1991 Bisphosphonates action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 20952105.
  • 11
    Rodan GA, Fleisch HA 1996 Bisphosphonates: Mechanism of action. J Clin Invest 97: 26922696.
  • 12
    The Writing Group for the PEPI Trial 1995 Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273: 199208.
  • 13
    Speroff L, Rowan J, Symons J, Genant H, Wilborn W for the CHART Study Group 1996 The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study). JAMA 276: 3971403.
  • 14
    Jones P, Kafonek S, Laurora I, Hunninghake D 1988 Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81: 582587.
  • 15
    Giselle MD, Jennifer AJ, McCloud PI, Davis SR 1997 Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 337: 595601.